Zimmer Biomet Prepares for Longer Downturn
The company's 3Q21 orthopedic sales declined -0.5% due to procedure delays, staffing shortages and larger-than-expected impact from China. Nov 05, 2021
Conformis Product Revenue Battered by Procedure Delays
The company's sales declined in the low double digits in 3Q21 due to procedure delays, with relief likely at some point in 2022. Nov 04, 2021
SeaSpine Increases Investments to Fuel Growth
SeaSpine grew in the high single digits for 3Q21 and continues its investments to drive share gains and growth. Nov 04, 2021
ConMed Maintains Cautious Outlook on Pandemic Recovery
The company grew in the low single digits for 3Q21 and anticipates a gradual recovery from declines brought on by the Delta variant. Nov 02, 2021
Stryker’s Organic Growth Impacted by Autumn Surges
The company's orthopedic business grew only 2% organically in 3Q21 due to the Delta variant and hospital staffing shortages. Nov 01, 2021
DePuy Synthes Expects Healthy Volume Recovery to End 2021
The company grew 0.5% in the third quarter of 2021 compared to the year prior as procedure declines peaked in July and August. Oct 20, 2021
IPO Landscape Favorable for Orthopedic Players
Three companies – Treace Medical Concepts, Bioventus and Paragon 28 – made the leap in 2021. Market conditions could induce more to go public in 2022. Oct 20, 2021
China’s Volume-Based Procurement Policy a Seismic Shift for Orthopedic Players
China's volume-based procurement policy recently came to hip and knee replacements, resulting in price declines of more than 80%. Sep 29, 2021
Royal Biologics Takes Diverse Approach to Autologous Live Cell Therapy
While autologous live cell therapies are not new, Royal Biologics is creating a unique value proposition through its growing ALC portfolio. Sep 22, 2021
Orthopedic Market Nears Normalization as 2021 Winds Down
The orthopedic market outperformed expectations in the first half of 2021, given gaps in vaccine coverage and the surging delta variant. Sep 08, 2021
